CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade TFF Pharmaceuticals, Inc. - TFFP CFD

    0.38
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* N/A
    Open* 0.38
    1-Year Change* -93.48%
    Day's Range* 0.38 - 0.38
    52 wk Range 0.32-6.05
    Average Volume (10 days) 83.05K
    Average Volume (3 months) 3.91M
    Market Cap 20.94M
    P/E Ratio -100.00K
    Shares Outstanding 56.09M
    Revenue 785.15K
    EPS -0.87
    Dividend (Yield %) N/A
    Beta 1.17
    Next Earnings Date Nov 13, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 15, 2023 0.38 0.00 0.00% 0.38 0.38 0.37
    Aug 24, 2023 0.38 0.01 2.70% 0.37 0.38 0.37
    Aug 23, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
    Aug 22, 2023 0.39 0.01 2.63% 0.38 0.39 0.38
    Aug 21, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
    Aug 16, 2023 0.37 -0.03 -7.50% 0.40 0.40 0.37
    Aug 15, 2023 0.39 -0.02 -4.88% 0.41 0.50 0.39
    Aug 14, 2023 0.40 -0.01 -2.44% 0.41 0.42 0.40
    Aug 11, 2023 0.39 0.00 0.00% 0.39 0.39 0.39
    Aug 8, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
    Aug 7, 2023 0.38 -0.02 -5.00% 0.40 0.45 0.38
    Aug 4, 2023 0.41 0.02 5.13% 0.39 0.42 0.39
    Aug 3, 2023 0.39 -0.02 -4.88% 0.41 0.41 0.39
    Aug 2, 2023 0.39 -0.03 -7.14% 0.42 0.43 0.39
    Aug 1, 2023 0.40 0.00 0.00% 0.40 0.41 0.40
    Jul 31, 2023 0.41 0.01 2.50% 0.40 0.41 0.39
    Jul 6, 2023 0.39 0.00 0.00% 0.39 0.39 0.39
    Jul 5, 2023 0.41 -0.06 -12.77% 0.47 0.47 0.39
    Jul 3, 2023 0.46 0.02 4.55% 0.44 0.47 0.44
    Jun 30, 2023 0.44 0.03 7.32% 0.41 0.44 0.41

    TFF Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Monday, November 13, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 TFF Pharmaceuticals Inc Earnings Release
    Q3 2023 TFF Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Tuesday, March 5, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q4 2023 TFF Pharmaceuticals Inc Earnings Release
    Q4 2023 TFF Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0.49581 0.08816 0 0 0
    Total Operating Expense 32.2926 31.8748 18.6936 11.9876 3.89815
    Selling/General/Admin. Expenses, Total 13.7963 10.5739 8.01209 3.16533 3.04934
    Research & Development 18.4963 21.3009 10.6816 8.82223 0.84881
    Operating Income -31.7968 -31.7867 -18.6936 -11.9876 -3.89815
    Net Income Before Taxes -31.7701 -31.0387 -18.5672 -11.8702 -3.84219
    Net Income After Taxes -31.7701 -31.0387 -18.5672 -11.8702 -3.84219
    Net Income Before Extra. Items -31.7701 -31.0387 -18.5672 -11.8702 -3.84219
    Net Income -31.7701 -31.0387 -18.5672 -11.8702 -3.84219
    Income Available to Common Excl. Extra. Items -31.7701 -31.0387 -18.5672 -36.6753 -4.57054
    Income Available to Common Incl. Extra. Items -31.7701 -31.0387 -18.5672 -36.6753 -4.57054
    Diluted Net Income -31.7701 -31.0387 -18.5672 -36.6753 -4.57054
    Diluted Weighted Average Shares 29.9798 24.821 20.4252 18.451 17.8254
    Diluted EPS Excluding Extraordinary Items -1.05972 -1.2505 -0.90904 -1.98772 -0.25641
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -1.05972 -1.2505 -0.90904 -1.98772 -0.25641
    Interest Income (Expense), Net Non-Operating 0.02673 0.05123 0.12642 0.11733 0.05596
    Total Adjustments to Net Income 0 -24.8051 -0.72835
    Revenue 0.49581 0.08816
    Other, Net 0 0.69671
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.33335 0.05143 0.31278 0.08759 0.028
    Revenue 0.33335 0.05143 0.31278 0.08759 0.028
    Total Operating Expense 5.35226 7.13788 7.69356 7.36821 8.80082
    Selling/General/Admin. Expenses, Total 2.67036 3.11922 3.55751 3.34227 3.69001
    Research & Development 2.6819 4.01866 4.13605 4.02594 5.11081
    Operating Income -5.01891 -7.08645 -7.38078 -7.28062 -8.77282
    Interest Income (Expense), Net Non-Operating -0.0013 0.03508 0.00754 0.00612 0.00588
    Other, Net 0 0 0.02061
    Net Income Before Taxes -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Net Income After Taxes -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Net Income Before Extra. Items -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Net Income -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Income Available to Common Excl. Extra. Items -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Income Available to Common Incl. Extra. Items -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Diluted Net Income -5.02021 -7.05137 -7.37323 -7.2745 -8.74633
    Diluted Weighted Average Shares 36.1931 36.1931 29.9798 25.4517 25.3737
    Diluted EPS Excluding Extraordinary Items -0.13871 -0.19483 -0.24594 -0.28582 -0.3447
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.13871 -0.19483 -0.24594 -0.28582 -0.3447
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Liabilities 1.13066 1.96075 1.32204 0.41064 1.157
    Accounts Payable 0.91961 1.49384 1.29773 0.41064 0.42865
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 1.24076 1.96075 1.32204 1.54265 1.157
    Total Long Term Debt 0 0 0 0 0
    Total Equity 22.8795 38.7371 37.3398 27.6448 9.24451
    Retained Earnings (Accumulated Deficit) -97.0884 -65.3184 -34.2797 -15.7124 -3.84219
    Total Liabilities & Shareholders’ Equity 24.1202 40.6978 38.6618 29.1874 10.4015
    Total Common Shares Outstanding 36.1931 25.3718 22.5349 18.451 17.8254
    Total Current Assets 19.0252 38.838 37.559 29.1874 10.2737
    Cash and Short Term Investments 16.6123 33.7947 35.3008 28.0949 10.2617
    Cash & Equivalents 16.6123 33.7947 35.3008 28.0949 10.2617
    Prepaid Expenses 2.22634 2.44793 2.25823 1.09246 0.01207
    Total Assets 24.1202 40.6978 38.6618 29.1874 10.4015
    Other Long Term Assets, Total 0.00769 0 0.12777
    Accrued Expenses 0.08506 0.41691 0 0.72835
    Preferred Stock - Non Redeemable, Net 12.486
    Common Stock 0.03619 0.02537 0.02254 0.01845 0.004
    Additional Paid-In Capital 120.071 104.079 71.6485 43.3387 0.59672
    Other Liabilities, Total 0.11009 0 1.13201
    Redeemable Preferred Stock 0
    Property/Plant/Equipment, Total - Net 3.27439 1.85986 1.10281
    Other Current Liabilities, Total 0.126 0.05 0.02432
    Other Equity, Total -0.1393 -0.04892 -0.05154
    Total Receivables, Net 0.18651 2.59535
    Note Receivable - Long Term 1.81298
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 13.9604 19.0252 16.979 25.1817 31.524
    Cash and Short Term Investments 12.2164 16.6123 13.1471 20.8902 26.4142
    Cash & Equivalents 12.2164 16.6123 13.1471 20.8902 26.4142
    Prepaid Expenses 1.55531 2.22634 1.06976 1.48395 2.16445
    Total Assets 18.2117 24.1202 20.2274 27.9132 33.7828
    Property/Plant/Equipment, Total - Net 2.40387 3.27439 3.24073 2.56439 2.25874
    Total Current Liabilities 1.57684 1.13066 2.07657 3.82751 2.19678
    Accounts Payable 1.34443 0.91961 1.63402 3.48046 2.02878
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.151 0.126 0.36271 0.268 0.168
    Total Liabilities 1.66837 1.24076 2.20489 3.9737 2.19678
    Total Long Term Debt 0 0 0 0 0
    Total Equity 16.5433 22.8795 18.0225 23.9395 31.586
    Common Stock 0.03619 0.03619 0.02552 0.02537 0.02537
    Additional Paid-In Capital 120.805 120.071 107.923 106.462 105.257
    Retained Earnings (Accumulated Deficit) -104.14 -97.0884 -89.7152 -82.4407 -73.6944
    Other Equity, Total -0.15796 -0.1393 -0.21035 -0.10712 -0.00169
    Total Liabilities & Shareholders’ Equity 18.2117 24.1202 20.2274 27.9132 33.7828
    Total Common Shares Outstanding 36.1931 36.1931 25.5181 25.3738 25.3718
    Total Receivables, Net 0.18877 0.18651 2.76214 2.80752 2.94541
    Accrued Expenses 0.08141 0.08506 0.07984 0.07905 0
    Other Long Term Assets, Total 0.00769 0.00769 0.00769 0.16708
    Other Liabilities, Total 0.09152 0.11009 0.12831 0.14619
    Note Receivable - Long Term 1.83969 1.81298
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -31.7701 -31.0387 -18.5672 -11.8702 -3.84219
    Cash From Operating Activities -27.3422 -29.557 -16.6156 -11.2161 -2.12699
    Changes in Working Capital -0.55108 -1.59719 -0.25982 0.06407 0.38612
    Cash From Investing Activities -1.55133 -0.86851 -1.10281 0 0
    Other Investing Cash Flow Items, Total 0 0
    Cash From Financing Activities 11.751 28.885 24.9947 29.0494 12.3887
    Financing Cash Flow Items 0 -0.09731
    Net Change in Cash -17.1824 -1.50613 7.20587 17.8333 10.2617
    Non-Cash Items 4.59076 2.96748 2.21146 0.59004 1.32907
    Issuance (Retirement) of Stock, Net 11.751 28.885 24.9947 29.0494 12.486
    Cash From Operating Activities 0.38822 0.11145 0
    Capital Expenditures -1.55133 -0.86851 -1.10281
    Foreign Exchange Effects -0.03987 0.03436 -0.0704
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -7.05137 -31.7701 -24.3968 -17.1223 -8.376
    Cash From Operating Activities -4.36578 -27.3422 -19.6402 -12.2607 -7.2463
    Cash From Operating Activities 0.12317 0.38822 0.26731 0.16617 0.07703
    Non-Cash Items 1.44312 4.59076 2.80813 1.87762 0.6527
    Changes in Working Capital 1.1193 -0.55108 1.68119 2.81779 0.39998
    Cash From Investing Activities 0 -1.55133 -1.41016 -0.63268 -0.13723
    Capital Expenditures 0 -1.55133 -1.41016 -0.63268 -0.13723
    Cash From Financing Activities -0.01792 11.751 0.41474 -0.016 0
    Issuance (Retirement) of Stock, Net 11.751 0.41474 0.01019 0
    Foreign Exchange Effects -0.01225 -0.03987 -0.01197 0.00501 0.00303
    Net Change in Cash -4.39596 -17.1824 -20.6476 -12.9044 -7.3805
    Financing Cash Flow Items -0.01792 -0.02618

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    TFF Pharmaceuticals, Inc. Company profile

    About TFF Pharmaceuticals Inc

    TFF Pharmaceuticals, Inc. is an early stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Voriconazole Inhalation Powder (VIP), TFF Tacrolimus Inhalation Powder (TIP) and Triple Combination. It is developing TFF VIP to treat invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF VIP is being developed as an inhaled dry powder drug. It is developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is developing Triple Combination, a dry powder drug combination to treat chronic obstructive pulmonary disease (COPD) and asthma. Its other dry powder products include Inhaled SARS-CoV2 Monoclonal Antibody, Niclosamide Inhalation Powder, Cannabidiol (CBD) and Vaccines.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, TFF Pharmaceuticals Inc revenues increased from $0K to $76K. Net loss increased 66% to $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $2.8M to $14.1M (expense), Stock-based Compensation in SGA increase of 98% to $2.4M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    2600 Via Fortuna Ste 360
    AUSTIN
    TEXAS 78746-7983
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    ETH/USD

    1,596.14 Price
    +0.480% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    BTC/USD

    26,288.45 Price
    +0.400% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Oil - Crude

    93.05 Price
    +3.250% 1D Chg, %
    Long position overnight fee 0.0588%
    Short position overnight fee -0.0807%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    XRP/USD

    0.51 Price
    -0.160% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading